The entire board of DNA testing company 23andMe resigned after a conflict with CEO Anne Wojcicki over her plan to take the ...

This proposal came as 23andMe's valuation plummeted from $6 billion in 2021 to under $150 million. The company has faced ...

With 23andme in a desperate situation and eyeing a potential sale, Medical Device Network examines what is set to happen to ...

A giant biotechnology company might be about to go bust. What will happen to the millions of people’s DNA it holds?

Over the past year, 23andMe set new corporate governance lows. CEO Anne Wojcicki now enters de facto “founder mode” after a ...

Stock splits are typically viewed as bullish indicators that a company sees more growth is on the horizon. Although nothing ...

Me helped usher in the era of consumer DNA test kits nearly two decades ago, but has more recently faced a series of setbacks ...

A spokesperson for 23andMe would not comment to NPR on what will happen to genetic data, except to express the company’s ...

Anne Wojcicki, the CEO of the consumer genetic testing company 23andMe (ME), is cautiously optimistic about the firm’s future ...

A huge data breach followed by a plummeting valuation has stoked fears of a sale of 23andMe along with all of its customers' genetic data.

Gray’s optimism on IPO markets provided a positive gloss to its muted asset sales in third-quarter results released on Thursday. The biggest story at Blackstone is its continued growth in almost any ...